As of June 30, 2026, AgomAb Therapeutics NV carries a market capitalization of 639.24M, placing it among publicly traded companies globally. Its enterprise value stands at 352.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 639.24M |
| Enterprise Value | 352.66M |
AgomAb Therapeutics NV's next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, AgomAb Therapeutics NV has 49.25M shares outstanding.
| Shares Outstanding | 49.25M |
These figures are as of June 30, 2026.
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.36 |
As of June 30, 2026, AgomAb Therapeutics NV maintains a current ratio of 12.88, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.88 |
| Quick Ratio | 12.55 |
| Debt / Equity | 0.43 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 62.00 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 9.38 |
As of June 30, 2026, AgomAb Therapeutics NV holds 287.88M in cash and equivalents against 1.30M in total debt, resulting in a net debt position of -253.16M. Total book value stands at 303.18M, with working capital of 272.38M providing operational flexibility.
| Cash & Cash Equivalents | 287.88M |
| Total Debt | 1.30M |
| Net Debt | -253.16M |
| Equity (Book Value) | 303.18M |
| Book Value Per Share | 6.16 |
| Working Capital | 272.38M |
These figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -4,569.86 |
Already premium?